Core E: Experimental Therapeutics Core
Core E: Experimental Therapeutics Core
批准号:
8933233
负责人:
JAMES E BRADNER
金额:
$16.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-04-15 至 2020-08-31
关键词:
Acute Graft Versus Host DiseaseAddressAllogenicAnalytical ChemistryAntibodiesAntigensB-LymphocytesBacteriaBiochemicalBiochemistry and Cellular BiologyBiologicalBiological MarkersBiological ModelsBiologyCell physiologyCellsCharacteristicsChemicalsChromatinChronicClinicalClinical ResearchClinical assessmentsCollaborationsComputational BiologyDevelopmentDiseaseDrug effect disorderEpigenetic ProcessFibrosisGoalsHistocompatibility TestingHistonesHumanImmuneImmunoglobulinsImmunologyInflammationInflammatory ResponseInsectaInterdisciplinary StudyLaboratoriesLeadershipMass Spectrum AnalysisMethodsModelingMolecularMorbidity - disease rateOrganic ChemistryOrganic SynthesisPathway interactionsPatientsPeptide SynthesisPeptidesPharmaceutical PreparationsPharmacologic SubstancePharmacologyPhasePre-Clinical ModelPreventionProductionProteinsReaderReagentRecombinant ProteinsResearchResearch InfrastructureResearch PersonnelS PhaseSeriesSignal PathwaySignal TransductionSolidSurface AntigensTechnologyTertiary Protein StructureTestingTherapeuticTherapeutic AgentsTherapeutic InterventionToxic effectTranslational ResearchTranslationsValidationYeastsbasechronic graft versus host diseaseclinical investigationclinical practicegraft vs host diseasehematopoietic cell transplantationin vivoinhibitor/antagonistinnovationinsightinterdisciplinary approachmortalitynovelnovel therapeuticspre-clinicalprogramsprototyperesponsesmall moleculesynthetic peptidetooltranslational studytreatment strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary Core E
The discovery, characterization and development of novel therapeutic strategies to ameliorate the morbidity
and mortality of graft-versus-host disease (GVHD) requires an interdisciplinary approach leveraging emerging
biological insights and novel pharmacologic strategies. Already, this Program has successfully developed new
and effective therapeutic interventions based on biological hypotheses tested in preclinical models of GVHD.
To accelerate the pace of research and to more immediately connect the preclinical and clinical programs, we
have created a new Experimental Therapeutics Core Laboratory. The goals of the Core are (a) to provide
immediate and unrestricted access to chemical probes, investigational agents and therapeutic substances for
preclinical and biological assessment, (b) to derive chemical derivatives of active agents to address disclosed
pharmacologic liabilities encountered in this research, as needed, (c) to provide high-purity synthetic peptides
allowing the validation of surface antigens and (d) to purify recombinant proteins or protein domains for the
characterization of putative alloreactive antibodies. Beyond these technical objectives, the leadership and staff
of the Experimental Therapeutics Core Laboratory will provide expertise in molecular pharmacology guiding
selection and use of chemical tools alone or in combination in biological and translational studies proposed
herein. As therapeutic agents enter human clinical investigation, the Core will contribute to the selection and
assessment of clinical biomarkers of drug action. The completion of these objectives will require the
development of new methods in organic synthesis, parallel solid-phase peptide synthesis, analytical chemistry,
protein production and mass spectrometry. As such, the Core is located in a state-of-the-art chemical biology
laboratory which possesses the infrastructure, expertise and technology required to complete the stated Aims
and to integrate inter-programmatic activities.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of Chromatin Signaling in Heart Failure by BET Bromodomain Proteins
-
批准号:9042034
-
项目类别:
-
资助金额:$88.17万
-
财政年份:2015
-
负责人:JAMES E BRADNER
-
依托单位:
Selective inhibition of BRDT for male contraception
-
批准号:8528971
-
项目类别:
-
资助金额:$24.33万
-
财政年份:2012
-
负责人:JAMES E BRADNER
-
依托单位:
Selective inhibition of BRDT for male contraception
-
批准号:8549777
-
项目类别:
-
资助金额:$23.09万
-
财政年份:2012
-
负责人:JAMES E BRADNER
-
依托单位:
Selective inhibition of BRDT for male contraception
-
批准号:8692994
-
项目类别:
-
资助金额:$23.65万
-
财政年份:2012
-
负责人:JAMES E BRADNER
-
依托单位:
Selective Inhibition of HDAC6 in Cancer Therapy
-
批准号:7921305
-
项目类别:
-
资助金额:$9.26万
-
财政年份:2009
-
负责人:JAMES E BRADNER
-
依托单位:
Selective Inhibition of HDAC6 in Cancer Therapy
-
批准号:7471815
-
项目类别:
-
资助金额:$13.92万
-
财政年份:2008
-
负责人:JAMES E BRADNER
-
依托单位:
Selective Inhibition of HDAC6 in Cancer Therapy
-
批准号:8304363
-
项目类别:
-
资助金额:$13.93万
-
财政年份:2008
-
负责人:JAMES E BRADNER
-
依托单位:
Selective Inhibition of HDAC6 in Cancer Therapy
-
批准号:7841867
-
项目类别:
-
资助金额:$13.93万
-
财政年份:2008
-
负责人:JAMES E BRADNER
-
依托单位:
Selective Inhibition of HDAC6 in Cancer Therapy
-
批准号:7628446
-
项目类别:
-
资助金额:$13.93万
-
财政年份:2008
-
负责人:JAMES E BRADNER
-
依托单位:
Selective Inhibition of HDAC6 in Cancer Therapy
-
批准号:8077392
-
项目类别:
-
资助金额:$13.93万
-
财政年份:2008
-
负责人:JAMES E BRADNER
-
依托单位:
Trageting the Multiple Myeloma Epigenome
-
批准号:8607272
-
项目类别:
-
资助金额:$24.01万
-
财政年份:2003
-
负责人:JAMES E BRADNER
-
依托单位:
Targeting the Multiple Myeloma Epigenome
-
批准号:9122369
-
项目类别:
-
资助金额:$24.35万
-
财政年份:2003
-
负责人:JAMES E BRADNER
-
依托单位:
Targeting the Multiple Myeloma Epigenome
-
批准号:8764976
-
项目类别:
-
资助金额:$24.36万
-
财政年份:2003
-
负责人:JAMES E BRADNER
-
依托单位:
Novel Epigenetic Approaches in AML
-
批准号:8666231
-
项目类别:
-
资助金额:$47.76万
-
财政年份:1997
-
负责人:JAMES E BRADNER
-
依托单位:
Core E: Experimental Therapeutics Core
-
批准号:9337371
-
项目类别:
-
资助金额:$15.81万
-
财政年份:--
-
负责人:JAMES E BRADNER
-
依托单位:
Novel Epigenetic Approaches in AML
-
批准号:9143047
-
项目类别:
-
资助金额:$47.11万
-
财政年份:--
-
负责人:JAMES E BRADNER
-
依托单位:
Novel Epigenetic Approaches in AML
-
批准号:8934701
-
项目类别:
-
资助金额:$47.11万
-
财政年份:--
-
负责人:JAMES E BRADNER
-
依托单位:
海外基金